ImmuCell Corp.

As of October 17, 2025, ImmuCell Corp. is considered overvalued with a valuation grade shift from attractive to expensive, highlighted by high Price to Book and EV to EBITDA ratios, negative return metrics, and a premium P/E ratio compared to peers, despite recent strong performance relative to the S&P 500.

As of October 17, 2025, ImmuCell Corp. is considered overvalued with a valuation grade shift to expensive, highlighted by a negative P/E ratio, low ROCE, and high Price to Book Value, despite outperforming the S&P 500 over the past year.

As of September 4, 2025, ImmuCell Corp. shows a mildly bullish trend overall, despite mixed signals from technical indicators and recent underperformance compared to the S&P 500.

As of August 14, 2025, ImmuCell Corp. is considered overvalued with a shift from risky to expensive due to high P/B and EV/EBITDA ratios, negative profitability metrics, and a significantly higher P/E ratio compared to peers, despite a recent strong performance relative to the S&P 500.

As of May 21, 2025, the technical trend has shifted to bullish, supported by strong indicators like a bullish MACD, moving averages, and Bollinger Bands across multiple time frames.

As of November 21, 2022, ImmuCell Corp. is considered overvalued with a risky valuation grade, reflected in its high Price to Book Value of 2.05 and EV to EBITDA of 26.30, despite a strong stock return of 47.12% over the past year.

As of March 2022, ImmuCell Corp.'s management team includes Dr. David Tomsche (Chairman), Mr. Michael Brigham (President and CEO), Ms. Bobbi Brockmann (VP of Sales and Marketing), and several Independent Directors: Mr. David Cunningham, Mr. Steven Rosgen, Mr. Jonathan Rothschild, and Mr. Paul Wainman. This team oversees the company's operations and strategic direction.

ImmuCell Corp. is an animal health company focused on developing products to enhance the health and productivity of dairy and beef cattle. As of March 2025, it reported net sales of $8 million and a net profit of $1 million, with a market cap of $57.57 million.

As of Jun 18, ImmuCell Corp. has a market capitalization of 57.57 million, categorizing it as a Micro Cap company, with net sales of 27.30 million and a net profit of -0.26 million over the latest four quarters.